PARP1 and cancer: By radiolabeling a small molecule PARP inhibitor with astatine-211 (211At), we developed the first-in-class alpha-emitting drug that targets cancer nuclei via PARP1, [211At]parthanatine ([211At]PTT) – previously referred to as [211At]MM47.